IX Biopharma (SGX:42C) reported that its iXB 401 semaglutide sublingual wafer demonstrated 20 times greater bioavailability than Rybelsus, an oral semaglutide tablet, in a preclinical study, according to a Tuesday filing on the Singapore Exchange.

The wafer uses iX Biopharma's sublingual drug delivery technology, offering a potentially more consistent and noninvasive alternative to oral semaglutide with lower variability, the filing said.